

Task Force on Repurposing of Drugs (TFORD) for COVID-19

Patent status in India: by GNANLEX

Tofacitinib

A. Active patents

S.no.	Title	Assignee	Patent details	Type of patent	Remarks
1.	Pyrrolo[2,3-D] pyrimidine compounds	Pfizer Products Inc.	Grant no: IN241773 Filing date: 10/06/2002 Grant date: 20/03/2009 Expected expiry date: 23/11/2020 Form 27: The Patent is working in India	Tofacitinib API, process for manufacture thereof and its standard dosage form	Patent Barrier upto 23/11/2020. Licensing options may be explored
2.	Crystalline 3-{{(3R,4R)-4-Methyl-3-[Methyl-[7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-Amino]-Piperidin-L-Yl}-3-Oxo-propionitrile mono citrate salt and its method of preparation	Toyama Chemical Co., Ltd	App no/Grant no: IN218212 (1095/DELNP/2004) Filing date: 23/04/2004 Grant date: 03/10/2008 Expected expiry date: 25/11/2022 Form 27: "the Patent is working in India".	Crystalline citrate salt of Tofacitinib	Patent Barrier. upto 25/11/2022. Licensing options may be explored
3.	Novel Tofacitinib Addition Salts And Process For The Preparation Thereof	Phalanx Labs Pvt Limited	App no/Grant no: IN328338 (7137/CHE/2015) Filing date: 31/12/2015 Grant date: 03/01/2020 Expected expiry date: 31/12/2035 Form 27: Not yet filed	Process For The Preparation of Tofacitinib	Patent Barrier However, can be worked around.

B. Pending applications - None

S.no.	Title	Assignee	Application details	Type of patent	Remarks
1.	A method for resolving enantiomers of a compound of the formula (iii)	Pfizer Products Inc	App no: 737/MUMNP/2011 Filing/Priority date: 15/04/2011/31/05/2001 Status: Under Examination	Enantiomers of Tofacitinib	Currently no patent barrier
2.	Process For Preparation Of Tofacitinib And Intermediates Thereof	Pfizer Products Inc	App no: 3684/MUM/2012 Filing/Priority date: 28/12/2012 Status: Under Examination	Intermediate and the process for preparation thereof for Tofacitinib	Currently no patent barrier
3.	Tofacitinib Oral Sustained Release Dosage Forms	Pfizer Products Inc	App no: 8222/DELNP/2015 Priority date: 16/03/2013 Status: Under Examination	Composition of Tofacitinib and an osmagen	Currently no patent barrier
4.	New Synthetic Route For The Preparation Of 3 Amino Piperidine Compounds	Lek Pharmaceuticals	App no: 460/KOLNP/2015 Priority date: 25/07/2012 Status: Under Examination	Intermediates which is used in the preparation of Tofacitinib	Currently no patent barrier

Commissioned by



Task Force on Repurposing of Drugs (TFORD) for COVID-19

Patent status in India: by GANLEX

5.	Preparation Of 3 Amino Piperidine Compounds Via Nitro Tetrahydropyridine Precursors	Lek Pharmaceuticals	App no: 1996/KOLNP/2015 Priority date: 30/11/2012 Status: Under Examination	Intermediates which is used in the preparation of Tofacitinib	Currently no patent barrier
6.	Resinates Of Tofacitinib for Taste Masking	Unichem Laboratories	App no: 201621007953 Priority date: 08/03/2016 Status: Awaiting Examination	Resinate of tofacitinib	Currently no patent barrier
7.	Resinates Of Tofacitinib for Taste Masking	Unichem Laboratories	App no: 201621007954 Priority date: 08/03/2016 Status: Awaiting Examination	Resinate of tofacitinib citrate.	Currently no patent barrier
8.	Improved Process For The Preparation Of Chiral 3-Amino-Piperidins, Useful Intermediates For The Preparation Of Tofacitinib	Fabbrica Italiana Sintetici S.p.A.	App no: 201844023522 Priority date: 29/06/2017 Status: Under Examination	Intermediate	Currently no patent barrier

C. Expired/Lapsed applications

S.no.	Title	Assignee	Application details	Type of patent	Remarks
1.	Chiral salt resolution	Pfizer Products Inc	App No: 991/MUMNP/2003 Filing Date: 27/10/2003 Status: Refused	Chiral salt of Tocilizumab	No patent barrier
2.	Tofacitinib citrate process and polymorphs	Dr. Reddys Laboratories Limited	App No: 4330/CHE/2013 Filing Date: 24/09/2013 Status: Withdrawn	Process and polymorphic forms of Tofacitinib citrate	No patent barrier
3.	Crystalline and non crystalline forms of tofacitinib and a pharmaceutical composition comprising tofacitinib and a penetration enhancer	Pfizer Inc	App No: 7857/DELNP/2013 Filing Date: 06/09/2013 Status: Abandoned	Crystalline, Non Crystalline Forms Of Tofacitinib And A Pharmaceutical Composition	No patent barrier
4.	Anti tofacitinib antibodies and uses thereof for drug monitoring	Pfizer Inc	App No: 8419/CHENP/2014 Filing Date: 19/11/2014 Status: Abandoned	Tofacitinib conjugate	No patent barrier
5.	Process for the preparation of	Ranbaxy Lab Ltd	App no : 5946/DELNP/2015	Intermediates which is used in	No patent barrier

Commissioned by



Task Force on Repurposing of Drugs (TFORD) for COVID-19

Patent status in India: by GNANLEX

	tofacitinib and intermediates thereof		Filing Date: 07/07/2015 Status: Abandoned	the preparation of Tofacitinib	
6.	Tofacitinib orally disintegrating tablets	Unichem Laboratories	App No: 2842/MUM/2015 Filing Date: 27/07/2015 Status: Withdrawn	Tofacitinib orally disintegrating tablets	No patent barrier
7.	Oral pharmaceutical composition of tofacitinib	Sun Pharmaceuticals	App No: 201617044915 Filing Date: 29/12/2016 Status: Withdrawn	Dry granulation process for the preparation of the composition comprises tofacitinib	No patent barrier

Disclaimer:

Search results are up to 21st May 2020

GNANLex's Opinion / Report as hereinabove is to the best of our knowledge, true and accurate as of the date compiled based on available information. However, no guarantee is made as to its accuracy, reliability or completeness. The final user is expected to assume sole liability for any patent infringement that occurs by following our recommendations or using the information given. Before using, user should determine the suitability of the information for his intended use. The risk and liability, if any, in connection therewith, is solely that of the user.

Commissioned by

